Dr David Cutter
Clinical Research Fellow (CTSU) and Consultant Clinical Oncologist (Oxford Cancer Centre)
David Cutter studied medicine at the University of Cambridge (1994-2000) and trained in Oncology at the Oxford Cancer Centre. In 2008 he joined CTSU to study for a DPhil on the late cardiovascular effects of cancer treatments. In 2013 he was appointed as a Consultant Clinical Oncologist and continues to work within CTSU upon a programme of work investigating the benefits and risks of cancer treatments.
Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography-Directed Therapy for Early-Stage Hodgkin Lymphoma.
Cutter DJ. et al, (2021), J Clin Oncol, 39, 3591 - 3601
Limited-stage diffuse large B-cell lymphoma: current management and challenges.
Zhang X-Y. et al, (2021), Br J Haematol
An Excess Mortality Risk Analysis of Proton Beam versus Optimal Photon Radiotherapy for Mediastinal Hodgkin Lymphoma: Who May Benefit Most?
Ntentas G. et al, (2020), INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 108, S140 - S141
Dose-response relationships for radiation-related heart disease: Impact of uncertainties in cardiac dose reconstruction.
Ntentas G. et al, (2020), Radiother Oncol
Risk of cerebrovascular disease among 13,457 five-year survivors of childhood cancer: a population based cohort study.
Reulen RC. et al, (2020), Int J Cancer